We conducted an open label , superiority , parallel design , randomized phase II trial comparing oral MCT -LSB- daily celecoxib ( @mg twice daily ) and weekly methotrexate ( @mg/m ( @ ) ) -RSB- to intravenous single agent cisplatin ( IP ) ( @mg/m ( @ ) ) given @ weekly .